Global Biomarker Clinical Phase Outsourcing Services Market Research Report 2023

Publication ID:

PB501245251

Publication Date:

January 4, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Computing & Electronics [3]

Description:

The global Biomarker Clinical Phase Outsourcing Services market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029.
Key companies engaged in the Biomarker Clinical Phase Outsourcing Services industry include ICON plc, Fujirebio lnc, Charles River Laboratories International,Inc., Laboratory Corporation of America Holdings, Parexel lnternational Corporation, Proteome Sciences plc, Eurofins Scientific, Wuxi AppTec Co., Ltd. and NorthEast BioAnalytical Laboratories LLC., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Biomarker Clinical Phase Outsourcing Services were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Biomarker Clinical Phase Outsourcing Services market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Biomarker Clinical Phase Outsourcing Services market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
ICON plc
Fujirebio lnc
Charles River Laboratories International,Inc.
Laboratory Corporation of America Holdings
Parexel lnternational Corporation
Proteome Sciences plc
Eurofins Scientific
Wuxi AppTec Co., Ltd.
NorthEast BioAnalytical Laboratories LLC.
Celerion, Inc.
GenScript ProBio Co.,Ltd.
Segment by Type
Predictive Biomarker
Prognostic Biomarker
Safety Biomarker
Surrogate Endpoints
Segment by Application
Pharmaceutical Companies
Biotechnology Companies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Biomarker Clinical Phase Outsourcing Services report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biomarker Clinical Phase Outsourcing Services Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Predictive Biomarker
1.2.3 Prognostic Biomarker
1.2.4 Safety Biomarker
1.2.5 Surrogate Endpoints
1.3 Market by Application
1.3.1 Global Biomarker Clinical Phase Outsourcing Services Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical Companies
1.3.3 Biotechnology Companies
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biomarker Clinical Phase Outsourcing Services Market Perspective (2018-2029)
2.2 Biomarker Clinical Phase Outsourcing Services Growth Trends by Region
2.2.1 Global Biomarker Clinical Phase Outsourcing Services Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Biomarker Clinical Phase Outsourcing Services Historic Market Size by Region (2018-2023)
2.2.3 Biomarker Clinical Phase Outsourcing Services Forecasted Market Size by Region (2024-2029)
2.3 Biomarker Clinical Phase Outsourcing Services Market Dynamics
2.3.1 Biomarker Clinical Phase Outsourcing Services Industry Trends
2.3.2 Biomarker Clinical Phase Outsourcing Services Market Drivers
2.3.3 Biomarker Clinical Phase Outsourcing Services Market Challenges
2.3.4 Biomarker Clinical Phase Outsourcing Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biomarker Clinical Phase Outsourcing Services Players by Revenue
3.1.1 Global Top Biomarker Clinical Phase Outsourcing Services Players by Revenue (2018-2023)
3.1.2 Global Biomarker Clinical Phase Outsourcing Services Revenue Market Share by Players (2018-2023)
3.2 Global Biomarker Clinical Phase Outsourcing Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biomarker Clinical Phase Outsourcing Services Revenue
3.4 Global Biomarker Clinical Phase Outsourcing Services Market Concentration Ratio
3.4.1 Global Biomarker Clinical Phase Outsourcing Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biomarker Clinical Phase Outsourcing Services Revenue in 2022
3.5 Biomarker Clinical Phase Outsourcing Services Key Players Head office and Area Served
3.6 Key Players Biomarker Clinical Phase Outsourcing Services Product Solution and Service
3.7 Date of Enter into Biomarker Clinical Phase Outsourcing Services Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biomarker Clinical Phase Outsourcing Services Breakdown Data by Type
4.1 Global Biomarker Clinical Phase Outsourcing Services Historic Market Size by Type (2018-2023)
4.2 Global Biomarker Clinical Phase Outsourcing Services Forecasted Market Size by Type (2024-2029)
5 Biomarker Clinical Phase Outsourcing Services Breakdown Data by Application
5.1 Global Biomarker Clinical Phase Outsourcing Services Historic Market Size by Application (2018-2023)
5.2 Global Biomarker Clinical Phase Outsourcing Services Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Biomarker Clinical Phase Outsourcing Services Market Size (2018-2029)
6.2 North America Biomarker Clinical Phase Outsourcing Services Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Biomarker Clinical Phase Outsourcing Services Market Size by Country (2018-2023)
6.4 North America Biomarker Clinical Phase Outsourcing Services Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biomarker Clinical Phase Outsourcing Services Market Size (2018-2029)
7.2 Europe Biomarker Clinical Phase Outsourcing Services Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Biomarker Clinical Phase Outsourcing Services Market Size by Country (2018-2023)
7.4 Europe Biomarker Clinical Phase Outsourcing Services Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market Size (2018-2029)
8.2 Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market Size by Region (2018-2023)
8.4 Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biomarker Clinical Phase Outsourcing Services Market Size (2018-2029)
9.2 Latin America Biomarker Clinical Phase Outsourcing Services Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Biomarker Clinical Phase Outsourcing Services Market Size by Country (2018-2023)
9.4 Latin America Biomarker Clinical Phase Outsourcing Services Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biomarker Clinical Phase Outsourcing Services Market Size (2018-2029)
10.2 Middle East & Africa Biomarker Clinical Phase Outsourcing Services Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Biomarker Clinical Phase Outsourcing Services Market Size by Country (2018-2023)
10.4 Middle East & Africa Biomarker Clinical Phase Outsourcing Services Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 ICON plc
11.1.1 ICON plc Company Detail
11.1.2 ICON plc Business Overview
11.1.3 ICON plc Biomarker Clinical Phase Outsourcing Services Introduction
11.1.4 ICON plc Revenue in Biomarker Clinical Phase Outsourcing Services Business (2018-2023)
11.1.5 ICON plc Recent Development
11.2 Fujirebio lnc
11.2.1 Fujirebio lnc Company Detail
11.2.2 Fujirebio lnc Business Overview
11.2.3 Fujirebio lnc Biomarker Clinical Phase Outsourcing Services Introduction
11.2.4 Fujirebio lnc Revenue in Biomarker Clinical Phase Outsourcing Services Business (2018-2023)
11.2.5 Fujirebio lnc Recent Development
11.3 Charles River Laboratories International,Inc.
11.3.1 Charles River Laboratories International,Inc. Company Detail
11.3.2 Charles River Laboratories International,Inc. Business Overview
11.3.3 Charles River Laboratories International,Inc. Biomarker Clinical Phase Outsourcing Services Introduction
11.3.4 Charles River Laboratories International,Inc. Revenue in Biomarker Clinical Phase Outsourcing Services Business (2018-2023)
11.3.5 Charles River Laboratories International,Inc. Recent Development
11.4 Laboratory Corporation of America Holdings
11.4.1 Laboratory Corporation of America Holdings Company Detail
11.4.2 Laboratory Corporation of America Holdings Business Overview
11.4.3 Laboratory Corporation of America Holdings Biomarker Clinical Phase Outsourcing Services Introduction
11.4.4 Laboratory Corporation of America Holdings Revenue in Biomarker Clinical Phase Outsourcing Services Business (2018-2023)
11.4.5 Laboratory Corporation of America Holdings Recent Development
11.5 Parexel lnternational Corporation
11.5.1 Parexel lnternational Corporation Company Detail
11.5.2 Parexel lnternational Corporation Business Overview
11.5.3 Parexel lnternational Corporation Biomarker Clinical Phase Outsourcing Services Introduction
11.5.4 Parexel lnternational Corporation Revenue in Biomarker Clinical Phase Outsourcing Services Business (2018-2023)
11.5.5 Parexel lnternational Corporation Recent Development
11.6 Proteome Sciences plc
11.6.1 Proteome Sciences plc Company Detail
11.6.2 Proteome Sciences plc Business Overview
11.6.3 Proteome Sciences plc Biomarker Clinical Phase Outsourcing Services Introduction
11.6.4 Proteome Sciences plc Revenue in Biomarker Clinical Phase Outsourcing Services Business (2018-2023)
11.6.5 Proteome Sciences plc Recent Development
11.7 Eurofins Scientific
11.7.1 Eurofins Scientific Company Detail
11.7.2 Eurofins Scientific Business Overview
11.7.3 Eurofins Scientific Biomarker Clinical Phase Outsourcing Services Introduction
11.7.4 Eurofins Scientific Revenue in Biomarker Clinical Phase Outsourcing Services Business (2018-2023)
11.7.5 Eurofins Scientific Recent Development
11.8 Wuxi AppTec Co., Ltd.
11.8.1 Wuxi AppTec Co., Ltd. Company Detail
11.8.2 Wuxi AppTec Co., Ltd. Business Overview
11.8.3 Wuxi AppTec Co., Ltd. Biomarker Clinical Phase Outsourcing Services Introduction
11.8.4 Wuxi AppTec Co., Ltd. Revenue in Biomarker Clinical Phase Outsourcing Services Business (2018-2023)
11.8.5 Wuxi AppTec Co., Ltd. Recent Development
11.9 NorthEast BioAnalytical Laboratories LLC.
11.9.1 NorthEast BioAnalytical Laboratories LLC. Company Detail
11.9.2 NorthEast BioAnalytical Laboratories LLC. Business Overview
11.9.3 NorthEast BioAnalytical Laboratories LLC. Biomarker Clinical Phase Outsourcing Services Introduction
11.9.4 NorthEast BioAnalytical Laboratories LLC. Revenue in Biomarker Clinical Phase Outsourcing Services Business (2018-2023)
11.9.5 NorthEast BioAnalytical Laboratories LLC. Recent Development
11.10 Celerion, Inc.
11.10.1 Celerion, Inc. Company Detail
11.10.2 Celerion, Inc. Business Overview
11.10.3 Celerion, Inc. Biomarker Clinical Phase Outsourcing Services Introduction
11.10.4 Celerion, Inc. Revenue in Biomarker Clinical Phase Outsourcing Services Business (2018-2023)
11.10.5 Celerion, Inc. Recent Development
11.11 GenScript ProBio Co.,Ltd.
11.11.1 GenScript ProBio Co.,Ltd. Company Detail
11.11.2 GenScript ProBio Co.,Ltd. Business Overview
11.11.3 GenScript ProBio Co.,Ltd. Biomarker Clinical Phase Outsourcing Services Introduction
11.11.4 GenScript ProBio Co.,Ltd. Revenue in Biomarker Clinical Phase Outsourcing Services Business (2018-2023)
11.11.5 GenScript ProBio Co.,Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

ICON plc
Fujirebio lnc
Charles River Laboratories International,Inc.
Laboratory Corporation of America Holdings
Parexel lnternational Corporation
Proteome Sciences plc
Eurofins Scientific
Wuxi AppTec Co., Ltd.
NorthEast BioAnalytical Laboratories LLC.
Celerion, Inc.
GenScript ProBio Co.,Ltd.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂